French pharma group Servier has formed a second partnership with Aitia focusing on the use of artificial intelligence and digital twins to help discover and develop new therapies for cancer.

There’s a whole lot to admire in this project. The swing-out transparent OLED display is super slick, the electronics are housed on a single PCB, the back half of the grip is in fact a portable ...

Servier looks like it could bring a second IDH inhibitor from its 2021 takeover of Agios’ oncology business to market, after reporting positive results in a phase 3 brain cancer trial.